Navigation Links
Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
Date:3/20/2008

SEATTLE, March 20 /PRNewswire/ -- Fred Hutchinson Cancer Research Center (FHCRC) and NSB POSTECH, Inc. (NSB) have reached a collaboration agreement to coordinate their efforts and to determine the efficacy of the NSB's NanoCones surface technology in creating high quality proteomic microarrays to be used in the study of human diseases.

NSB is a South Korean biotech company which possesses a proprietary microarray technology and a great deal of expertise in nano-scale controlled surface chemistry. NSB has agreed to fund the collaboration.

Announced today, this collaboration will involve a comparison of slides created with NSB's newly developed NanoCones surface technology and the current industry standard.

"This is the first time a Korean biotech company has had an opportunity to collaborate with a major U.S.-based cancer research center. We are very thrilled to be working with scientists at the Hutchinson Center," said Dr. Joon Won Park, president of NSB and one of the inventors of the NanoCones technology.

"We are excited about the preliminary data that has been generated when antibodies were arrayed using the NanoCones technology. We hope this will make our antibody arrays more sensitive and accurate," said Dr. Paul Lampe, member of the Hutchinson Center's Public Health Sciences Division and associate program head of molecular diagnostics.

Antibody or protein microarrays are glass microscope slides onto which very small amounts of thousands of different antibodies or proteins have been affixed at distinct locations. Antibody microarrays can be used to simultaneously determine the level of each antibody's specific binding partner in complex mixtures such as blood so thousands of different assays can be performed with small amounts of sample.

At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, visit http://www.fhcrc.org.

NSB POSTECH, Inc. is a South Korea based Biotech Company specializing in nano-surface technology for genomic and proteomic microarrays. NSB's mission is to detect and prevent disease. NanoCones technology research was funded with support from POSCO, Korea's world-renowned steel manufacturer and POSTECH, one of Asia's leading Science and Technology Universities. For more information, visit http://www.nsbpostech.com.


'/>"/>
SOURCE NSB POSTECH, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
(Date:5/24/2016)... Worcester, Mass. (PRWEB) , ... May 24, 2016 ... ... including heart attacks, diabetes, and traumatic injuries, will be accelerated by research at ... skin cells into engines of wound healing and tissue regeneration. , The novel ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... a newly re-branded identity. The new Media Cybernetics corporate branding reflects a results-driven ... of imaging and image analysis. The re-branding components include a crisp, refreshed logo ...
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):